AR Asset Management’s Marker Therapeutics MRKR Stock Holding History

AR Asset Management’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-73,700	Closed	-$91K	–	116
2025 Q1	$91K	Hold	73,700	–	–	0.02%	113
2024 Q4	$229K	Hold	73,700	–	–	0.05%	108
2024 Q3	$208K	Buy	73,700 +3,000	+4%	+$11.9K	0.05%	112
2024 Q2	$384K	Hold	70,700	–	–	0.09%	97
2024 Q1	$304K	Hold	70,700	–	–	0.07%	101
2023 Q4	$389K	Hold	70,700	–	–	0.1%	96
2023 Q3	$321K	Buy	70,700 +30,000	+74%	+$168K	0.09%	97
2023 Q2	$126K	Hold	40,700	–	–	0.03%	110
2023 Q1	$29K	Buy	+40,700	New	+$96.8K	0.01%	112
2022 Q4	–	Sell	-27,900	Closed	-$103K	–	113
2022 Q3	$103K	Hold	27,900	–	–	0.03%	115
2022 Q2	$92K	Hold	27,900	–	–	0.03%	119
2022 Q1	$123K	Buy	27,900 +20,750	+290%	+$119K	0.03%	117
2021 Q4	$68K	Sell	7,150 -20,750	-74%	-$276K	0.02%	116
2021 Q3	$472K	Sell	27,900 -100	-0.4%	-$2.05K	0.13%	97
2021 Q2	$781K	Buy	+28,000	New	+$737K	0.22%	78

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

INVST Indianapolis, Indiana $886M AUM 21.79% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

AR Asset Management's MRKR Position: Q2 2025 in Review

AR Asset Management sold out of Marker Therapeutics (MRKR) in Q2 2025, closing a stake of 73,700 shares — an estimated $91K sold.

AR Asset Management first reported a position in MRKR in Q2 2021 and held it in 15 quarters. The position peaked at $781K in Q2 2021. 31 funds tracked by Wall St. Rank hold MRKR as of Q2 2025.

AR Asset Management reported no remaining Marker Therapeutics position as of Q2 2025 after selling out during the quarter.
AR Asset Management sold 73,700 Marker Therapeutics shares in Q2 2025, an estimated $91K.
AR Asset Management first reported a position in Marker Therapeutics in Q2 2021 and held it in 15 quarters.
AR Asset Management's Marker Therapeutics position peaked at $781K in Q2 2021.
31 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2025.

Based on AR Asset Management's 13F filing for Q2 2025, filed 6 Aug 2025.